The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2014 | Breakthrough in relapsed multiple myeloma with PANORAMA 1 study
At the 19th Congress of the European Hematology Association (EHA) meeting, Prof Paul Richardson, of Dana-Farber Cancer Institute, Boston, MA, discusses the results of PANORAMA 1, which was a global randomized, double-blind, placebo-controlled phase 3 trial of panobinostat in combination with bortezomib and dexamethasone in patients with relapsed multiple myeloma. Prof Richardson outlines the primary end-point results and side effects observed, and comments on the clinical meaningfulness of these results. Results of subsets of higher risk groups are also discussed, and Prof Richardson comments on new data with ricolinostat (ACY-1215) in multiple myeloma.
